PFM Health Sciences’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$58.2M Buy
+455,300
New +$56.8M 5.3% 3
2025
Q1
Sell
-179,100
Closed -$16.1M 94
2024
Q4
$16.1M Buy
+179,100
New +$17.4M 1% 33
2020
Q4
Sell
-200,000
Closed -$22.3M 106
2020
Q3
$22.3M Sell
200,000
-238,100
-54% -$26.7M 1.03% 37
2020
Q2
$49M Buy
+438,100
New +$43.1M 2.54% 11
2019
Q4
Sell
-1,143,600
Closed -$87.2M 82
2019
Q3
$87.2M Buy
+1,143,600
New +$95M 2.58% 8
2018
Q4
Sell
-648,700
Closed -$62.2M 126
2018
Q3
$62.2M Buy
+648,700
New +$62.9M 0.91% 45
2018
Q1
Sell
-1,127,200
Closed -$95.7M 102
2017
Q4
$95.7M Buy
+1,127,200
New +$94.4M 2.27% 8

Other funds holding XBI

PFM Health Sciences's XBI Position: Q4 2024 in Review

PFM Health Sciences sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2024, closing a stake of 121,845 shares — an estimated $11.8M sold.

PFM Health Sciences first reported a position in XBI in Q4 2016 and held it in 3 quarters. The position peaked at $39.9M in Q3 2017. 738 funds tracked by Wall St. Rank hold XBI as of Q4 2024.

  • PFM Health Sciences reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2024 after selling out during the quarter.
  • PFM Health Sciences sold 121,845 State Street SPDR S&P Biotech ETF shares in Q4 2024, an estimated $11.8M.
  • PFM Health Sciences first reported a position in State Street SPDR S&P Biotech ETF in Q4 2016 and held it in 3 quarters.
  • PFM Health Sciences's State Street SPDR S&P Biotech ETF position peaked at $39.9M in Q3 2017.
  • 738 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2024.

Based on PFM Health Sciences's 13F filing for Q4 2024, filed 14 Feb 2025.